Mindfulness Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Attention Deficit Hyperactivity Disorder (ADHD)
Mindful Awareness Practices (MAPs) - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

It is estimated that 25-40% of youth with ADHD have co-occurring cognitive disengagement syndrome (CDS; previously sluggish cognitive tempo), a set of behavioral symptoms characterized by excessive daydreaming, slowed thinking, and mental confusion and fogginess. A growing body of research demonstrates CDS to be associated with functional impairment above and beyond that which can be accounted for by ADHD severity. However, no treatment currently exists that directly targets CDS symptoms. This is a critical clinical and scientific gap, leaving youth with ADHD and co-occurring CDS at risk for experiencing negative immediate and long-term outcomes. In considering intervention approaches, mindfulness meditation involves regular practice to catch oneself when the mind wanders, and may thus an ideal intervention for youth with CDS. However, mindfulness interventions, including the Mindful Awareness Practices (MAPs) for ADHD, have never been tested in adolescents with ADHD and co-occurring CDS specifically. This study will recruit up to 15 adolescents with ADHD and co-occurring CDS symptoms to enroll in an open trial of MAPs to evaluate its feasibility, acceptability, and preliminary efficacy. Findings will provide key pilot data regarding treatment of CDS in adolescents with ADHD.

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Immediately after the intervention

Immediately after the intervention
Attention Deficit Disorder
Syndrome
Change in mind wandering: Mind-Wandering Questionnaire (MWQ)
Mindfulness

Trial Safety

Trial Design

1 Treatment Group

Mindfulness Treatment
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Mindfulness Treatment · No Placebo Group · N/A

Mindfulness Treatment
Behavioral
Experimental Group · 1 Intervention: Mindful Awareness Practices (MAPs) · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mindful Awareness Practices (MAPs)
2017
N/A
~90

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: immediately after the intervention

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor
749 Previous Clinical Trials
5,418,408 Total Patients Enrolled
30 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
3,411 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Eligibility Criteria

Age < 18 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are between 13 and 17 years of age at the first MAPs session.
You have a T-score of 60 or higher on the SCT.
You must have sufficient English language ability to complete study measures and intervention per parent and/or research staff judgment.
If applicable: If the adolescent is taking a medication for ADHD or another psychiatric disorder (e.g.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.